# A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT05886491** · PHASE1,PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 16 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** GDX012
- **DRUG:** Chemotherapy Agents

## Key facts

- **NCT ID:** NCT05886491
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-11
- **Primary completion:** 2025-08-20
- **Final completion:** 2025-11-30
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Sponsor decision (No safety concern)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886491, "A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05886491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*